Thus, not only compound 2 reduced eWAT weight but it also robustly reduced the expression of inflammatory genes such as Tnf-α and Cd11b, thus reversing the pro-inflammatory phenotype that is typically observed in NASH patients. Here, ITGAM is linked to metabolic dysfunction-associated steatohepatitis.